Barzolvolimab not checked
Celldex Therapeutics · CDX-0159
FollowEvery change as it happens, and a Monday email
Trials
6 active
13 in total · 7 in the EU
Targets
—
None known yet
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Chronic Spontaneous Urticaria (3 trials), Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism, Prurigo Nodularis, Atopic Dermatitis
- Main trialPhase 3
- “The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.”In the company’s words, NCT06455202 on ClinicalTrials.gov
- Other names
- CDX-0159
Other drugs for Chronic Spontaneous Urticaria
Coming up2
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 12 NovCompletion date moved: 2026-10 to 2026-08-12 · ClinicalTrials.gov NCT06445023
- 12 NovCompletion date moved: 2026-10 to 2026-08-04 · ClinicalTrials.gov NCT06455202
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 4 Aug 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | |
| Phase 3Active, not recruiting | 12 Aug 2026 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | |
| Phase 3Recruiting | Jun 2028 | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD) | |
| Phase 3Enrolling by invitation | Sep 2028 | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | |
| Phase 2Active, not recruiting | 17 Mar 2026 | A Study of Barzolvolimab in Patients With Prurigo Nodularis | |
| Phase 2Active, not recruiting | 6 May 2026 | A Study of Barzolvolimab in Patients With Atopic Dermatitis | |
| Phase 2Completed | 28 Sep 2023 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | |
| Phase 2Completed | 12 Jun 2024 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | |
| Phase 2Completed | 4 Jun 2025 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | |
| Phase 1Completed | 14 Jan 2022 | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects | |
| Phase 1Completed | 16 Dec 2022 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | |
| Phase 1Completed | 17 Jan 2023 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | |
| Phase 1Completed | 31 Jul 2023 | A Study of CDX-0159 in Patients With Prurigo Nodularis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026